Skip to main content

Table 1 Demographics and baseline characteristics for patients receiving palbociclib plus endocrine therapy with/without dose reduction

From: Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

CharacteristicPalbociclib plus endocrine therapy*
Patients with dose reduction, 125 to 100 mg (N = 311)Patients without dose reduction (N = 550)Pooled ITT population (N = 875)
Age, years
 Mean (range)59.9 (32–88)60.0 (30–89)59.9 (30–89)
 < 65, n (%)192 (61.7)366 (66.5)571 (65.3)
 ≥ 65, n (%)119 (38.3)184 (33.5)304 (34.7)
Race, n (%)
 White211 (67.8)451 (82.0)672 (76.8)
 Black7 (2.3)14 (2.5)21 (2.4)
 Asian77 (24.8)64 (11.6)145 (16.6)
 Other16 (5.1)21 (3.8)37 (4.2)
Weight, mean (range), kg67.9 (33.0–123.0)72.4 (39.7–156.8)70.6 (33.0–156.8)
Height, mean (range), cm159.7 (134.6–182.9)161.3 (138.0–187.0)160.7 (134.6–187.0)
Measurable disease, n (%)225 (72.3)435 (79.1)671 (76.7)
Prior chemotherapy for advanced/metastatic disease, n (%)32 (10.3)68 (12.4)113 (12.9)
Disease site, n (%)
 Visceral146 (46.9)299 (54.4)452 (51.7)
 Nonvisceral165 (53.1)251 (45.6)423 (48.3)
 Bone only84 (27.0)117 (21.3)206 (23.5)
Number of disease sites involved, n (%)
 1103 (33.1)167 (30.4)272 (31.1)
 286 (27.7)141 (25.6)231 (26.4)
 369 (22.2)131 (23.8)203 (23.2)
 437 (11.9)68 (12.4)106 (12.1)
 516 (5.1)29 (5.3)47 (5.4)
Disease stage at initial diagnosis,ǁn (%)
 I28 (9.0)47 (8.5)77 (8.8)
 II99 (31.8)152 (27.6)257 (29.4)
 III45 (14.5)95 (17.3)141 (16.1)
 IV75 (24.1)148 (26.9)224 (25.6)
 Other8 (2.6)13 (2.4)21 (2.4)
 Unknown/missing23 (7.4)46 (8.4)71 (8.1)
 Not collected33 (10.6)49 (8.9)84 (9.6)
  1. ITT intent-to-treat
  2. *Patients in PALOMA-1 and PALOMA-2 received palbociclib plus letrozole; patients in PALOMA-3 had endocrine-resistant metastatic breast cancer and received palbociclib plus fulvestrant
  3. Data from patients who started on a dose < 125 mg are not included in the table
  4. Not reported/missing patients
  5. ǁStage at initial diagnosis was not collected for PALOMA-1